1. Response: dexamethasone dose alters expression of NK activating receptors in vivo
by Andy Hsu, Hang Quach, Tsin Tai, H. Miles Prince, Simon J. Harrison, Joseph A. Trapani, Mark J. Smyth, Paul J. Neeson, and David S. Ritchie
Blood
Volume 118(24):
December 8, 2011
©2011 by American Society of Hematology

2. NK cell–activating receptors in newly diagnosed patients treated with lenalidomide and ultra low dose dexamethasone.
NK cell–activating receptors in newly diagnosed patients treated with lenalidomide and ultra low dose dexamethasone. NK cell–activating receptors (DNAM-1, 2B4, NKG2D, NKp46, NKp30 an NKp44) were analyzed on CD16+CD56+ NK cells from 5 newly diagnosed patients on induction therapy (IC) receiving 25 mg/d lenalidomide and 60 mg/cycle of dexamethasone, and 13 newly diagnosed patients on maintenance therapy with lenalidomide only. Data are presented as mean fluorescence intensity (MFI), a significant difference in MFI between groups is represented by * (P = < .05).
Andy Hsu et al. Blood 2011;118:
©2011 by American Society of Hematology